metyylialonihappo

Metyylialonihappo is not a standard entry in chemical nomenclature. The form appears to be a misspelling or regional variant of metyylmalonihappo, which in Finnish corresponds to methylmalonic acid. There is no widely recognized chemical with the label “metyylialonihappo” as a distinct compound in major databases.

If the intended term is methylmalonic acid, it is a carboxylic acid that arises as a metabolite in the breakdown of certain amino acids and odd-chain fatty acids. In human metabolism, methylmalonyl-CoA is converted to succinyl-CoA by the enzyme methylmalonyl-CoA mutase, a reaction that requires adenosylcobalamin (a form of vitamin B12) as a cofactor. This places MMA at a key junction between amino acid and fatty acid catabolism and the citric acid cycle.

Clinically, methylmalonic acid is used as a biomarker for vitamin B12 status and for diagnosing certain metabolic disorders, such as methylmalonic acidemia and other cobalamin-related defects. In healthy individuals, MMA levels in blood and urine are relatively low; elevations can indicate impaired B12-dependent enzymatic activity or inherited metabolic conditions. Lab testing typically measures MMA in plasma, serum, or urine using methods such as LC-MS/MS or GC-MS, with results interpreted alongside other clinical and laboratory data.

In summary, while “metyylialonihappo” does not denote a distinct recognized compound, it is likely a misspelling of methylmalonic acid, a metabolite of propionate metabolism with significance in nutrition and metabolic disease. See also methylmalonyl-CoA mutase, vitamin B12, and methylmalonic acidemia.